Navigation Links
HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference

BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that new data presented at an international influenza research conference demonstrates that HepaLife's patented PBS-1 cell line outperforms current cell technologies at replicating human influenza virus inside its cells. The most important step towards the production of a cell-culture based vaccine against a targeted virus is the ability to efficiently grow the same virus in a cell substrate.

Data presented at the "Options for the Control of Influenza VI Conference," June 17-23, 2007, in Toronto, Canada, compared human influenza virus replication capabilities of several established cell lines. HepaLife's PBS-1 cell line significantly outperformed today's prevailing cell systems, including VERO (African green monkey kidney cell), MDCK ("Martin-Darby Canine Kidney") and primary chick kidney cells ("CEK").

(Click here to download HepaLife's PBS-1 cell line research results: http://www.hepalife.com/Smith_et_al-2007_-_PBS1_Poster.pdf)

"I'm very proud of the efforts that our research team has made in demonstrating the superiority of HepaLife's PBS-1 cells at an international conference dedicated to identifying cutting-edge solutions to influenza," commented Mr. Frank Menzler, President and CEO of HepaLife Technologies, Inc. "I'm especially pleased that our cell line is able to successfully grow targeted human influenza virus where other leading commercial and academically-researched cells lines have either failed to keep up, or are simply unable to do so."

According to test results, HepaLife's PBS-1 cells developed higher influenza 'titers' -- or concentration of influenza -- than CEK cells. In contrast, MDCK and VERO cells were unable to replicate virus and produce comparable results. Importantly, the tested influenza strains had not been previously adapted to any of the cel
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
2. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
3. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
4. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
5. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
6. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
7. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
8. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
9. Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetixs AAGP
10. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
11. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells
Post Your Comments:
(Date:5/16/2008)...ting that TYKERB and trastuzumab together resulted...on-free survival (PFS), -- Combining TYKERB and t...f the HER2 receptor may create a more complete HER...ERB alone despite patients,previous treatment wit... LONDON and PHILADELPHIA, May 16 /PRNewswire-USNew...
(Date:5/16/2008)...er Novel Approach to Blood ...swire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), a...vel small,molecule therapeutics, announced today t...tor Antagonist (DARA), showed statistically signif...y in patients with mild to,moderate hypertension. ...
(Date:5/15/2008)... Patients with breast or,colorectal cancer, two of...er treatment advances with Avastin(R) (bevacizumab...a that is being presented at the 44th,American Soc... Chicago at,the end of May. Around 30,000 medical ...er event for cancer therapy worldwide., The Roche...
(Date:5/15/2008)...table Tolerability Profile, with Low I...AKE, N.J., May 15 /- The investigatio...9) demonstrated activity in a,heavily pretreated p...atic,breast cancer, according to results of a mult...uggests that eribulin mesylate has a manageable,to...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 1ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 2ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 3ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 4Naturally occurring apple compounds reduce risk of pancreatic cancer 668 1Naturally occurring apple compounds reduce risk of pancreatic cancer 668 2Type of ICU Influences Lung Injury Survival 2811 1Type of ICU Influences Lung Injury Survival 2811 2Study Finds Benefits With Drug Coated Stents 2808 1Study Finds Benefits With Drug Coated Stents 2808 2Study Finds Benefits With Drug Coated Stents 2808 3
...BUSINESS WIRE)--Jun 20, 2007 - Array BioPharma,Inc...ta on its MEK,inhibitor, ARRY-162, and its p38 inh...the Annual European Congress of Rheumatology,(EULA...ssociation,of Inflammation Societies, (IAIS) 8th W...rk., ARRY-162 / MEK Inhibitor Phase 1 Results , Ar...
...chusetts --- June,20, 2007 --- Millipore Corporati...ing its ReNcell neural stem cell lines. The,resea...at,University College London and ReNeuron Group pl...pore was announced in 2006. ,The data will be pres...ientist for Millipore’s Bioprocess Division,...
Other Medicine Technology:Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 2Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 3Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 4Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 2Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 3Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 4
(Date:5/16/2008)...asize the Importance of Oral and Overall Health, ...ental insurer United,Concordia Dental is celebrati...ral Health America and the British Dental Health F... to overall health. Beginning May 18,this year,s ...rst time,making it the largest independent intern...
(Date:5/16/2008)...d at the American Society of Clinical Oncology mee...ment practice in about 25 percent of patients with...s to the way colorectal cancers will be staged. ,...e (NCI) SEER population-based statistic registries...ata, shows that outcomes of patients with positive...
(Date:5/16/2008)...sufferers gain benefit from calcitriol, an oral fo...- Taking activated vitamin D may cut the risk of d...dney disease by about one quarter, a new study sug...1,400 patients, those being treated with calcitrio...overall risk of death lowered by 26 percent when c...
(Date:5/16/2008)...t beneath the lining of the uterus (submucosal) ar...ter uterine artery embolization (UAE) but usually ... study. , The study included 49 patients with 1...e and after UAE. The study found that 39 of these ...ometrial cavity after UAE, said Sachit Verma, MD, ...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
...harles Schumer was very upset and has sent a lette...ration, Dr. Andrew von Eschenbach. In his letter h...he problem.// The confusion started when it was r...d for the patients in case of tissue transplants. ...
...dic Hospital and Beach Resort, located close to Ko...packages for treatment of what is called new-age a...drome (CTS). //The unique health care service wou...eram chief Poly Mathew said Monday: "The hospital ...
... who found a birthmark in her child Matilda found ... internet search to understand the birthmark in he...said her not to panic after a little internet brow...e she contacted Great Ormond Street hospital, Lond...
...n study researchers have seen that people over 60 ... risk of dementia than teetotalers. The Medical Jo...s the lifestyle risk factors for developing dement... research of a sample of 2805 over-60s from Dubbo,...
Other Medicine News:
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: